Biotech entity
All 4 tracked stories fall under one category: pharma. Boston Scientific is most often covered alongside Medtronic, which appears in 2 of these 4 stories. Each story carries 4.5 original sources on average, compared with 3.5 for the broader beat in this window.
Last mentioned: Sep 2, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 4 tracked stories fall under one category: pharma. Boston Scientific is most often covered alongside Medtronic, which appears in 2 of these 4 stories. Each story carries 4.5 original sources on average, compared with 3.5 for the broader beat in this window. The 182-day window averages about 0.2 stories each week. At 6.5, the average consequence score sits above the same-window beat average of 6.1. We currently track 4 Biotech stories that mention Boston Scientific, published between February 27, 2026 and August 27, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 667 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Boston Scientific. Shared-story counts are live from our verified record — not editorial picks.
Investigation remains unresolved
SecurityWeek reports no known cybercrime group has claimed responsibility; full scope, nature, and financial impact remain unknown.
Disclosure and market reaction
Company announces global operational disruption, including order processing and shipping systems; shares fall about 4% in morning trading. Evercore ISI estimates a 600-700 bps Q3 revenue impact if recovery mirrors Stryker's three-week timeline.
Cyber incident detected
Boston Scientific detects a cybersecurity incident affecting some IT systems.
Lead Plaintiff Deadline
Expected deadline for shareholders to petition the court to serve as lead plaintiff in the case.
Follow-up Disclosure
Secondary announcements highlight the filing and the process for shareholders to join the litigation.
Class Action Announcement
Pomerantz LLP first alerts investors to the class action filing against Boston Scientific.
Boston Scientific's August 25 cyberattack has disrupted global order processing and shipping, creating clinical and financial uncertainty for the medical device maker. Evercore ISI estimates a 600-700 basis point hit to Q3 revenue if recovery follows Stryker's roughly three-week timeline. The company has not yet determined whether the incident will be material.
Source: SecurityWeek
Pomerantz LLP has initiated a class action lawsuit against Boston Scientific (BSX), alleging potential violations of federal securities laws. The litigation centers on the company's disclosures during a period of significant expansion and product integration, marking a critical legal challenge for the medical device giant.
Q4 2025 earnings for specialized biotech firms reveal a sector-wide shift toward high-margin manufacturing and strategic divestitures. While Codexis capitalizes on its Merck partnership and ECOsynthesis platform, Elutia has cleared its debt through an $88 million divestiture to Boston Scientific.
The Australian government is significantly reducing subsidies for high-cost spinal cord stimulators following reports of severe patient injuries and a lack of clinical efficacy. This regulatory shift targets a multi-million dollar sector of the medical device market, forcing manufacturers to justify the high price tags of chronic pain technologies.
Boston Scientific is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
